Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Soleno Therapeutics, Inc. (SLNO) for potential corporate wrongdoing. The firm encourages investors who purchased Soleno securities before May 26, 2025, and continue to hold them, to connect and assist with the investigation. The investigation aims to restore investor capital and ensure corporate accountability, with no cost to Soleno investors unless the firm is successful in court.
Soleno Therapeutics withdraws European application for PWS treatment
Soleno Therapeutics has withdrawn its marketing authorization application for VIOKAT in Europe, citing business and strategic considerations. The decision allows the company to re-engage with regulators later if a suitable pathway emerges. The withdrawal follows Neurocrine Biosciences' acquisition of Soleno for $53 per share, which prompted several analyst downgrades for Soleno but an upgraded price target for Neurocrine.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Soleno Therapeutics, Inc. (SLNO) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Soleno securities before May 26, 2025, and still hold them, to join the investigation. This investigation aims to restore investor capital and ensure corporate accountability.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Soleno Therapeutics, Inc. (NASDAQ:SLNO). The firm encourages investors who purchased Soleno securities before May 26, 2025, and still hold them, to join the investigation. The investigation aims to restore investor capital and ensure corporate accountability, with the firm representing investors on a contingency-fee basis.
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) on behalf of shareholders who purchased securities before May 26, 2025, concerning potential corporate wrongdoing by the company's officers and directors. The law firm encourages affected investors to contact them to assist with the investigation, emphasizing that their representation is on a contingency fee basis. Peretz Bronstein, founding partner, highlighted the firm's focus on restoring investor capital and ensuring corporate accountability.
Soleno Therapeutics Inc (SLNO) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Soleno Therapeutics Inc (SLNO), highlighting major institutional investors and their holdings. It breaks down shareholder types and provides a historical overview of institutional shareholding changes, including the number of institutions, shares held, and proportional changes over several quarters. Key shareholders like Fidelity Management & Research Company LLC and Wellington Management Company, LLP are listed with their respective equity proportions and recent changes.
Soleno Therapeutics Inc (SLNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Soleno Therapeutics Inc (SLNO). It indicates that relevant data for business segments, and regional and profit contribution for FY2025, FY2025Q4, FY2025Q3, and FY2025Q2 have not yet been disclosed by the company. The article only notes a United States revenue of $190.41 million with 0.00% proportion from a 'By Region' section, without further context.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Soleno Therapeutics, Inc. (SLNO) shareholders who purchased securities before May 26, 2025, and still hold them. The investigation focuses on whether Soleno's officers and/or directors engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information, emphasizing that they operate on a contingency fee basis.
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Soleno Therapeutics presented new data at ENDO 2026 showing that VYKAT® XR (diazoxide choline) provides meaningful and durable improvements in hyperphagia and behavioral symptoms in patients with Prader-Willi Syndrome (PWS), even after a randomized withdrawal period. Participants who resumed treatment experienced improvements as early as Week 13, continuing for up to two years. The data also highlighted sustained benefits for up to three years compared to real-world information from the PATH for PWS Natural History Study.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Soleno Therapeutics, Inc. (NASDAQ:SLNO) and some of its officers and directors. The law firm is encouraging shareholders who purchased Soleno securities before May 26, 2025, and still hold them, to come forward and assist with the investigation. The firm operates on a contingency fee basis, meaning investors will not incur costs unless the firm is successful in recovering funds.
3-year VYKAT XR trial eases hyperphagia, behaviors in PWS
Soleno Therapeutics, a Neurocrine Biosciences company, presented new Phase 3 data at ENDO 2026 for VYKAT XR (diazoxide choline), demonstrating significant and sustained improvements in hyperphagia and behavioral symptoms associated with Prader-Willi syndrome over three years. Participants who restarted VYKAT XR after a 16-week randomized withdrawal period showed durable benefits in hyperphagia and behaviors, while continuous treatment maintained these improvements. The study also highlighted the drug's efficacy compared to natural history controls and stable BMI over two years.
Soleno Therapeutics Announces Late-Breaking Data At Endo 2026
Soleno Therapeutics presented new data at ENDO 2026 regarding its drug VYKAT® XR for Prader-Willi syndrome. The data demonstrated that resuming VYKAT XR after a randomized withdrawal period led to significant and sustained improvements in hyperphagia and behavioral symptoms over two years. Participants who continued uninterrupted therapy also maintained these durable benefits, reinforcing the drug's efficacy for long-term management of PWS.
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Soleno Therapeutics, a Neurocrine Biosciences company, presented new data at ENDO 2026 showing that VYKAT® XR (diazoxide choline) provided durable and meaningful improvements in hyperphagia and behavioral symptoms in patients with Prader-Willi syndrome (PWS). Participants who resumed VYKAT XR after a 16-week randomized withdrawal period regained treatment benefits, with sustained improvements observed for up to two years. The data also demonstrated statistically significant and sustained improvements compared to natural history data from the PATH for PWS study, strengthening VYKAT XR's profile as a long-term treatment option for PWS.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Soleno Therapeutics, Inc. (NASDAQ:SLNO) regarding potential corporate wrongdoing by its officers and directors. The law firm is encouraging investors who purchased Soleno securities prior to May 26, 2025, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis and seeks to recover investor capital and ensure corporate accountability.
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ: SLNO) for alleged corporate wrongdoing by its officers and/or directors. The firm is encouraging shareholders who purchased Soleno securities prior to May 26, 2025, and still hold them, to contact them to assist in the investigation. The representation is on a contingency fee basis, meaning no upfront cost to investors.
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring the Healthcare Biotech Leader’s Steady Trajectory
Soleno Therapeutics, Inc. (SLNO), a biotech company focused on rare diseases and a subsidiary of Neurocrine Biosciences, is highlighted for its lead product candidate VYKAT XR targeting Prader-Willi Syndrome. The article analyzes SLNO's stock performance, noting its current trading price of $53.01, a $2.76 billion market cap, and strong financial health with a 26.38% return on equity and over $91 million in free cash flow. While analysts currently rate it as a "hold" with a target price of $53.00, technical indicators suggest a bullish short-term trend, though it's nearing overbought territory.
NBIX: Multi-product growth, major acquisition, and robust pipeline drive strong financial and patient impact
Neurocrine Biosciences (NBIX) is undergoing a significant transformation into a multi-product, high-growth company with strong cash flow and diversified revenue. This growth is driven by the recent acquisition of Soleno Therapeutics, which expands its rare endocrine franchise, and robust R&D investments supporting a broad pipeline. The information is based on an AI-generated summary from the company's 46th Annual William Blair Growth Stock Conference Audio Transcript from June 2, 2026.
[15-12G] SOLENO THERAPEUTICS INC SEC Filing
This article reports on Soleno Therapeutics Inc.'s SEC Form 15-12G filing, which certifies the termination of registration under Section 12(g) of the Securities Exchange Act of 1934 or suspension of duty to file reports. The filing dated May 28, 2026, indicates that the company now has only one holder of record. Darin M. Lippoldt, President and Secretary, signed the certification.
[EFFECT] SOLENO THERAPEUTICS INC SEC Filing
This article reports on an EFFECT SEC filing by Soleno Therapeutics Inc. (SLNO), indicating its neutrality for both filing impact and sentiment. The filing, a Notice of Effectiveness, was dated May 27, 2026, with an accession number of 0001193125-26-234441 and submission type POS AM. The company operates in the Biotechnology industry within the Pharmaceutical Preparations sector and is headquartered in Redwood City, United States.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC announced an investigation into Soleno Therapeutics, Inc. (SLNO) for potential corporate wrongdoing. The firm encourages Soleno stockholders who purchased securities before May 26, 2025, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Soleno Therapeutics (SLNO) Investor Outlook: Navigating the Hold Ratings with Promising EPS and Cash Flow
Soleno Therapeutics (NASDAQ: SLNO) is a biopharmaceutical company focused on rare disease treatments, with a lead candidate VYKAT XR for Prader-Willi Syndrome. Despite current "hold" ratings from analysts and a static stock price, the company demonstrates strong financial health with impressive EPS of 1.93 and $91.67 million in Free Cash Flow. While the market adopts a cautious "wait-and-see" approach, Soleno's solid financial metrics and innovative potential suggest a promising long-term outlook for investors willing to ride out its developmental phase.
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Soleno Therapeutics, Inc. (NASDAQ:SLNO) regarding potential corporate wrongdoing. The firm is encouraging stockholders who purchased Soleno securities before May 26, 2025, and still hold them, to contact them to learn more about the investigation and assist in their claims. This investigation aims to restore investor capital and ensure corporate accountability.
Soleno Therapeutics (NASDAQ: SLNO) deregisters 3,000,000-share resale after merger
Soleno Therapeutics has filed a post-effective amendment to deregister a 3,000,000-share resale, confirming the termination of the registration following its merger into Neurocrine Biosciences. The amendment addresses an administrative filing error and formally removes all unsold or unissued securities under Registration No. 333-275120 as of May 21, 2026. This action eliminates the registered resale capacity and is a procedural step subsequent to the merger agreement dated April 5, 2026.
Soleno (SLNO) director’s shares cashed out at $53 per-share merger price
Soleno Therapeutics director Matthew Pauls disposed of his equity stake, consisting of 10,491 common shares and a 9,063-share stock option, as part of a merger where Soleno became a wholly owned subsidiary of Neocrine Biosciences. All shares, RSUs, and options were converted into the right to receive $53.00 in cash per share. This transaction was not an open-market sale but rather a standard cash-out process due to the acquisition.
Soleno Therapeutics (Nasdaq:SLNO) - Stock Analysis
This article provides a stock analysis of Soleno Therapeutics (Nasdaq:SLNO), detailing its valuation, future growth prospects, past performance, and financial health. Key recent updates include its acquisition by Neurocrine Biosciences, Inc. for $2.8 billion, a securities class action lawsuit regarding its DCCR program, and various changes in executive leadership and financial forecasts. The company's lead product, VYKAT XR, for Prader-Willi Syndrome, recently received FDA approval and commercial availability.
Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger
Soleno Therapeutics (NASDAQ: SLNO) has filed a post-effective amendment to deregister all unsold securities previously registered under Form S-3. This action follows the completion of a merger on May 18, 2026, which resulted in Soleno becoming a wholly owned subsidiary of Neurocrine Biosciences, Inc. The deregistration terminates the effectiveness of Registration Statements Nos. 333-275120 and 333-276344, removing any remaining unsold securities.
Soleno Therapeutics (SLNO) CFO has RSUs and stock options cashed out in Neocrine merger
Soleno Therapeutics' CFO, Jennifer Fulk, had her restricted stock units (RSUs) and stock options cashed out as part of Soleno's merger into a wholly owned subsidiary of Neocrine Biosciences. A total of 39,200 RSU shares and an employee stock option covering 67,660 shares were cancelled, with RSU holders receiving $53.00 per share in cash and option holders receiving a cash payment based on the difference between the merger consideration and the exercise price. After these transactions, Fulk holds no remaining equity from these awards.
Soleno Therapeutics (NASDAQ: SLNO) taken private at $53 per share in cash deal
Neurocrine Biosciences has completed its acquisition of Soleno Therapeutics (NASDAQ: SLNO) for $53.00 per share in cash, with approximately 88.9% of shares tendered. Following the tender offer, Soleno merged into Neurocrine's subsidiary on May 18, 2026, becoming a wholly owned subsidiary. As a result, Soleno will be delisted from Nasdaq, deregistered with the SEC, and its previous loan agreement and employee stock purchase plan have been terminated.
Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger
Soleno Therapeutics (NASDAQ: SLNO) has filed a Post-Effective Amendment to its S-3 registration statements to deregister any unsold securities following its merger with Neurocrine Biosciences, Inc. The deregistration occurred on May 18, 2026, after Soleno became a wholly owned subsidiary of Neurocrine Biosciences, Inc. This action is a routine post-closing administrative step to terminate the effectiveness of the registration statements.
Soleno Therapeutics (SLNO) Nasdaq submits Form 25 to remove common stock
Nasdaq Stock Market LLC has filed a Form 25 to delist Soleno Therapeutics Inc.'s (SLNO) common stock from the exchange and/or withdraw its registration under Section 12(b) of the Exchange Act. This action signifies a formal removal process, although the exact effective date for delisting and subsequent steps for shareholders are not detailed in this filing. The filing indicates compliance with regulatory procedures for delisting, and investors are cautioned that delisting can impact a stock's visibility, trading volume, and price volatility.
Soleno Therapeutics (SLNO) CBO equity canceled, cashed out at $53 per share
Soleno Therapeutics' Chief Business Officer, Kevin Norrett, cashed out his equity holdings, including RSUs and stock options, as part of the company's merger with Neocrine Biosciences. All holdings were converted into cash at a rate of $53.00 per share, resulting in Norrett holding no direct shares or options after the transactions. The transaction details were reported in a Form 4 SEC filing, outlining the disposition of 17,786 RSU-based shares and two stock option grants totaling 68,286 shares.
Soleno Therapeutics (SLNO) CCO equity cancelled, converted to $53 cash in merger
Soleno Therapeutics' Chief Commercial Officer, Meredith Manning, had her equity holdings, including 64,507 common shares and several employee stock options, cancelled and converted into a cash payment of $53.00 per share. This transaction occurred on May 18, 2026, as part of Soleno's merger with Neurocrine Biosciences. The Form 4 filing confirms that all of Manning's reported equity awards in Soleno were disposed of back to the issuer, reflecting the change from equity to cash consideration following the merger.
Soleno (SLNO) director’s 10,046 RSUs canceled for $53 cash in merger
Soleno Therapeutics director Mark W. Hahn reported the disposition of 10,046 restricted stock units (RSUs) that were canceled as part of a merger where Soleno became a wholly owned subsidiary of Neocrine Biosciences, Inc. Each RSU was converted into the right to receive $53.00 in cash. Following this transaction, Hahn holds no direct shares of Soleno common stock.
Soleno Therapeutics (SLNO) CEO fully cashed out as $53-per-share merger closes
Soleno Therapeutics CEO Anish Bhatnagar disposed of all his company equity, including common shares, RSUs, and stock options, in connection with Soleno's cash merger with Neocrine Biosciences. The transactions occurred on May 18, 2026, where all equity was converted into cash at a fixed $53.00 per share merger consideration. This Form 4 filing confirms the completion of the cash-out and indicates Bhatnagar holds zero remaining Soleno shares or options, as the company is now a wholly-owned subsidiary of Neocrine Biosciences.
Soleno Therapeutics (SLNO) director exits as $53-per-share cash merger closes
Soleno Therapeutics director Dawn Carter reported a disposition of 16,991 shares of Common Stock in connection with the company’s acquisition by Neocrine Biosciences, Inc. through its subsidiary Sigma Merger Sub, Inc. The merger, which occurred on May 18, 2026, resulted in each outstanding share and restricted stock unit being cancelled and converted into the right to receive $53.00 in cash. Following this transaction, Carter no longer holds any Soleno shares.
Soleno Therapeutics (SLNO) CDO equity cancelled for $53 cash in merger
Soleno Therapeutics' Chief Development Officer, Manher Joshi, disposed of all his equity holdings, including restricted stock units and stock options, as part of Soleno's merger into Neurocrine Biosciences. These holdings were cancelled and converted into a cash payment of $53.00 per share. Following these transactions, Joshi holds no remaining common stock or options in Soleno Therapeutics.
Neurocrine (SLNO) completes tender offer; ~46.36M Soleno shares tendered
Neurocrine Biosciences completed its acquisition of Soleno Therapeutics, with approximately 88.9% of Soleno's outstanding common stock (46.36 million shares) tendered at $53.00 per share. The tender offer closed on May 15, 2026, with Neurocrine accepting the shares on May 17, 2026, leading to a merger where Soleno became a wholly-owned subsidiary. Plans are underway to delist Soleno shares from Nasdaq and terminate its reporting obligations.
Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from S&P Biotechnology Select Industry Index
Soleno Therapeutics, Inc. (NasdaqCM:SLNO) has been removed from the S&P Biotechnology Select Industry Index. This news follows a period of significant activity for the company, including an earnings report for the first quarter ended March 31, 2026, and several analyst downgrades with adjusted price targets. The company is focused on developing therapeutics for rare diseases, with its primary product VYKAT XR for Prader-Willi syndrome.
Avoro and Aghazadeh report 4.45% stake in Soleno (NASDAQ: SLNO)
Avoro Capital Advisors LLC and Behzad Aghazadeh have each reported a beneficial ownership of 2,300,000 shares of Soleno Therapeutics (NASDAQ: SLNO), representing a 4.45% stake in the company. This disclosure was made via an amended Schedule 13G/A filing with the SEC, indicating the shares were acquired for investment purposes. The percentage is based on 51,718,149 shares outstanding as of March 31, 2026, with both parties having sole voting and dispositive power over their respective shares.
Wellington affiliates disclose 8.57% stake in Soleno Therapeutics (SLNO)
Wellington Management Group LLP and its affiliated entities have reported a beneficial ownership of 8.57% in Soleno Therapeutics (SLNO), comprising 4,426,781 shares. This updated disclosure, filed as a Schedule 13G/A, indicates a passive investment where shares are held for clients of multiple Wellington investment advisers, with shared voting and dispositive powers. The filing emphasizes that this is an institutional disclosure, not signaling direct corporate control.
State Street (SLNO) holds 2.68M shares, 5.2% stake in Soleno Therapeutics
State Street Corporation has disclosed a beneficial ownership of 2,680,802 shares in Soleno Therapeutics Inc. (SLNO), representing a 5.2% stake as of March 31, 2026. This Schedule 13G filing indicates that State Street holds shared voting and dispositive power over these shares, with no sole control by any single entity. The filing outlines the various State Street adviser entities involved in this investment.
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO). The lawsuit, with a lead plaintiff deadline of May 5, 2026, alleges that Soleno misrepresented safety concerns related to its Phase 3 clinical trial for DCCR, specifically regarding excess fluid retention. This misrepresentation purportedly inflated the commercial viability of DCCR and obscured significant safety risks and potential adverse regulatory and reputational fallout.
SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman
Hagens Berman has alerted investors in Soleno Therapeutics (SLNO) about a pending securities class action lawsuit, with a lead plaintiff deadline of May 5, 2026. The lawsuit alleges that Soleno misrepresented the safety, efficacy, and commercial viability of its drug VYKAT™ XR for Prader-Willi syndrome, including downplaying safety concerns and inflating launch metrics. These alleged misrepresentations led to significant stock declines following reports from an activist short seller and lower-than-expected Q3 2025 financial results.
Soleno Therapeutics faces final earnings test before buyout By Investing.com
Soleno Therapeutics is preparing to report its final earnings as an independent company before its acquisition by Neurocrine Biosciences for $53 per share. Analysts are looking closely at the performance of Vykat XR, the company's Prader-Willi syndrome treatment, given previous questions about management's confidence and the drug's blockbuster potential. While the stock now trades near the acquisition price, the earnings report will offer insight into the drug's commercial trajectory and adoption rates.
Soleno Therapeutics faces final earnings test before buyout
Soleno Therapeutics is reporting its first-quarter earnings, likely its last as an independent company, before its acquisition by Neurocrine Biosciences for $53 per share. Analysts are closely watching Vykat XR revenue figures to gauge the drug's continued success and whether the acquisition price adequately values its potential. The market expects earnings of $0.68 per share on revenue of $93.78 million, with preliminary product revenue already indicating continued sequential growth.
Number of shareholders of Soleno Therapeutics, Inc. – NASDAQ:SLNO
This article provides financial information for Soleno Therapeutics, Inc. (NASDAQ: SLNO). It lists the stock ticker, market, and offers an overview of financials, news, and other data for the company. The main focus is on the number of shareholders, though the specific value is not directly visible in the provided text.
Soleno Therapeutics (SLNO) Q4 Profitability Jump Tests Longstanding Bearish Earnings Narratives
Soleno Therapeutics (SLNO) reported a significant swing to profitability in Q4 2025, with revenue of US$91.7 million and EPS of US$0.81, marking a clear departure from previous losses. The article discusses how this rapid shift challenges historical bearish earnings narratives, highlighting the tension between the company's high P/E ratio and strong growth forecasts versus past losses and potential future risks. It suggests further analysis is needed to assess the durability of this newfound profitability.
Soleno Therapeutics (SLNO) Q4 Profitability Jump Tests Longstanding Bearish Earnings Narratives
Soleno Therapeutics (SLNO) reported a significant swing to profitability in Q4 2025, with revenue reaching US$91.7 million and basic EPS of US$0.81, marking a clear turnaround from previous quarterly losses. This rapid shift challenges long-standing bearish narratives, though a high P/E ratio and past losses introduce caution. Investors are urged to examine growth, risks, and valuation beyond the headlines.
Soleno Therapeutics (SLNO) Q4 Profitability Jump Tests Longstanding Bearish Earnings Narratives
Soleno Therapeutics (SLNO) reported a significant swing to profitability in Q4 2025, with revenue of US$91.7 million and basic EPS of US$0.81, marking a clear departure from previous quarterly losses. This sharp turnaround challenges long-standing bearish narratives, though the company's high P/E ratio and historical losses still present mixed signals for investors. Both bullish and bearish cases are discussed, highlighting the tension between rapid growth and the durability of this newfound profitability.
EDGAR Filing Documents for 0001193125-26-162715
This SEC EDGAR filing details a SC TO-T (Tender offer statement by Third Party) filed by SIGMA MERGER SUB, INC. on April 20, 2026, accepted on the same day. It concerns Neurocrine Biosciences Inc. as the entity making the filing and Soleno Therapeutics Inc. as the subject of the tender offer, providing their respective company and addressing information. The filing includes a list of 25 associated documents and data files.
